Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system
Based on the FAERS database, this study comprehensively and systematically analyzed AE signals in tralokinumab treatment. The results enhance the understanding of tralokinumab's safety and serve as valuable references for reducing the risk of adverse reactions during clinical use.
Authors
- Zeping Yang
- Jie Chen (ORCID: https://orcid.org/0000-0002-8337-183X)
- Kejing Tang (ORCID: https://orcid.org/0000-0002-5454-4666)
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1080/14740338.2024.2410434
- Citations
- 3
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Wu Jieping Medical Foundation